Jiayun Liu

Union Hospital
Wuhan, 430022, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Asian consensus on diagnostic algorithm for invasive pulmonary fungal diseases in high-burden settings.

Asian consensus on diagnostic algorithm for invasive pulmonary fungal diseases in high-burden settings.

Journal: Journal of translational internal medicine

Published: August 27, 2026

A radiomics-based nomogram for preoperatively predicting the invasiveness of nodular lung adenocarcinoma: a multicenter study.

A radiomics-based nomogram for preoperatively predicting the invasiveness of nodular lung adenocarcinoma: a multicenter study.

Journal: Translational lung cancer research

Published: October 31, 2025

Anti-CD24 Antibody Plus Liposomal Doxorubicin for the Management of Residual Cancers After Incomplete Radiofrequency Ablation.

Anti-CD24 Antibody Plus Liposomal Doxorubicin for the Management of Residual Cancers After Incomplete Radiofrequency Ablation.

Journal: ImmunoTargets and therapy

Published: May 29, 2025

Atezolizumab Plus Bevacizumab Combined with or without Transarterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Study.

Atezolizumab Plus Bevacizumab Combined with or without Transarterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Study.

Journal: Journal of hepatocellular carcinoma

Published: January 23, 2025

Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma.

Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma.

Journal: Cell death & disease

Published: October 25, 2024

Transarterial Chemoembolization Plus Radiofrequency Ablation and Iodine-125 Seed Implantation for Hepatocellular Carcinoma in High-Risk Locations: A Propensity Score-Matched Analysis.

Transarterial Chemoembolization Plus Radiofrequency Ablation and Iodine-125 Seed Implantation for Hepatocellular Carcinoma in High-Risk Locations: A Propensity Score-Matched Analysis.

Journal: Journal of hepatocellular carcinoma

Published: October 25, 2024

HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: A multicenter study.

HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: A multicenter study.

Journal: iScience

Published: September 03, 2024

Enhancing the therapeutic impact of sublethal radiofrequency hyperthermia in malignant solid tumor treatment.

Enhancing the therapeutic impact of sublethal radiofrequency hyperthermia in malignant solid tumor treatment.

Journal: Heliyon

Published: February 13, 2024

Correction: Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation.

Correction: Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation.

Journal: Journal of nanobiotechnology

Published: December 03, 2023

Radiofrequency hyperthermia enhances the effect of OK-432 for Hepatocellular carcinoma by activating of TLR4-cGAS-STING pathway.

Radiofrequency hyperthermia enhances the effect of OK-432 for Hepatocellular carcinoma by activating of TLR4-cGAS-STING pathway.

Journal: International immunopharmacology

Published: November 18, 2023

Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma.

Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: June 18, 2023

Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation.

Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation.

Journal: Journal of nanobiotechnology

Published: June 12, 2023

Showing 1-12 of 15

Last Updated: 09/26/2026